Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

BACKGROUND: Biological considerations suggest that renin–angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin–angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jordana B, Hanff, Thomas C, William, Preethi, Sweitzer, Nancy, Rosado-Santander, Nelson R, Medina, Carola, Rodriguez-Mori, Juan E, Renna, Nicolás, Chang, Tara I, Corrales-Medina, Vicente, Andrade-Villanueva, Jaime F, Barbagelata, Alejandro, Cristodulo-Cortez, Roberto, Díaz-Cucho, Omar A, Spaak, Jonas, Alfonso, Carlos E, Valdivia-Vega, Renzo, Villavicencio-Carranza, Mirko, Ayala-García, Ricardo J, Castro-Callirgos, Carlos A, González-Hernández, Luz A, Bernales-Salas, Eduardo F, Coacalla-Guerra, Johanna C, Salinas-Herrera, Cynthia D, Nicolosi, Liliana, Basconcel, Mauro, Byrd, James B, Sharkoski, Tiffany, Bendezú-Huasasquiche, Luis E, Chittams, Jesse, Edmonston, Daniel L, Vasquez, Charles R, Chirinos, Julio A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832152/
https://www.ncbi.nlm.nih.gov/pubmed/33422263
http://dx.doi.org/10.1016/S2213-2600(20)30558-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832152/
https://www.ncbi.nlm.nih.gov/pubmed/33422263
http://dx.doi.org/10.1016/S2213-2600(20)30558-0

Ejemplares similares